t315i mutation testing , page-8

I expect CXS will be seeking tissue samples (if available) on these 35% of patients on the pivotal trial if indeed they don't already have them, in order to confirm their T315I status. While I have no intimate knowledge of the clinical trial other than what has been made public, it would be standard medical (Haematological Oncology) practice to have retained blood samples or bone marrow biopsy results from the patients on the trial. Consent would have been obtained from the trial participants to use these tissue samples.